RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

RxSight, Inc.NASDAQ: RXST

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $759K (cash outflow) rose 32.0% year over year, ahead of the -0.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 33.2% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.

Context

  • Capital expenditures amounted to 2.8% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +32.0% holds above the trailing-twelve-month pace of -0.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$759K-33.2% QoQ
Last fiscal yearDec 2025
-$3.83M-29.6% YoY
LTMMar 2026
-$4.01M-0.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.0%——
1 year-29.6%——
3-year CAGR+17.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(3.83M) USD
Year-over-year change
+29.6%

Capital Expenditures vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 capital expenditures of $4.01M is the 3rd largest of the 9 companies compared; the peer median is $3.34M.
  • Its year-over-year change of -0.8% is the 8th highest of 9, against a peer median of +50.8%.
  • Capital expenditures amounts to 3.1% of revenue for RXST, versus a peer median of 2.2%.
RXST Competitors Peer median
Capital Expenditures for RXST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMCITreace Medical Concepts, Inc.LTM Mar 2026$13.04M +16.3%-3.1%6.3%
KIDSOrthoPediatrics Corp.LTM Mar 2026$8.64M -28.2%+3.5%3.6%
RXSTRxSight, Inc.LTM Mar 2026$4.01M -0.8%+17.0%3.1%
BFLYButterfly Network, Inc.LTM Mar 2026$3.95M +106.7%-43.2%3.8%
CERSCerus CorporationLTM Mar 2026$3.85M +108.1%+12.4%1.7%
TCMDTactile Systems Technology, Inc.LTM Mar 2026$2.84M +17.5%+7.4%0.8%
DCTHDelcath Systems, Inc.LTM Mar 2026$1.98M +188.2%+94.9%2.2%
NPCENeuroPace, Inc.LTM Mar 2026$412K +72.4%-18.0%0.4%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$36.19K +29.2%-21.0%—
Peer median (excluding RXST) $3.34M+50.8%+0.2%2.2%

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Depreciation & Amortization3.99M4.02M4.24M3.62M3.27M
Deferred Income Tax(5.4M)0000
Stock-Based Compensation7.58M11.4M15.75M24.64M31.61M
Change in Working Capital(2.68M)(7.41M)(9.07M)(9.21M)(4.89M)
Accounts Receivables(2M)(6.09M)(9.33M)(9.8M)6.66M
Inventory(2.11M)(7.56M)(2.75M)(4.99M)(11.48M)
Accounts Payables555K635K1.25M946K627K
Other Working Capital874K5.6M1.75M4.64M(692K)
Other Non-Cash Items493K(101K)(3.9M)(8.54M)(6.55M)
Operating Cash Flow(44.71M)(58.85M)(41.59M)(16.95M)(15.51M)
Capital Expenditures(1.94M)(2.39M)(4.81M)(5.44M)(3.83M)
Acquisitions (Net)79.97M(42.34M)17.32M00
Purchases of Investments(159.97M)(212.66M)(272.32M)(336.87M)(239.28M)
Sales of Investments80M255M255M243M260M
Other Investing Activities(79.97M)42.34M(17.32M)00
Investing Cash Flow(81.91M)39.95M(22.13M)(99.31M)16.89M
Debt Repayment14.97M(121K)(40.15M)(61K)(26K)
Common Stock Issued121.14M7.83M105.96M128.92M3.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.23M(1.38M)(4.28M)(5.54M)(2.06M)
Financing Cash Flow137.34M6.33M61.52M123.32M1.86M
Effect of Forex Changes(10K)(9K)6K(9K)2K
Net Change in Cash10.72M(12.58M)(2.19M)7.05M3.24M
Free Cash Flow(46.65M)(61.24M)(46.41M)(22.39M)(19.34M)

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.